OncoMatch/Clinical Trials/NCT06586242
Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy
Is NCT06586242 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin for esophageal cancer.
Treatment: Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin — This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT2N1-3M0, CT3N0-3M0, CT4N0-3M0, STAGE II-IVA (TNM)
clinical diagnosis is ct2n1-3m0 or ct3n0-3m0 or ct4n0-3m0, and the TNM stage is stage ii-iva
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
bone marrow function basically normal; significant myelosuppression [excluded]
Kidney function
kidney function basically normal
Liver function
liver function basically normal
Cardiac function
heart function basically normal; exclusion for myocardial ischemia/infarction, arrhythmia, cardiac insufficiency
the investigator assessed that the thyroid, lung, bone marrow, liver, kidney and heart functions were basically normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify